The addition of carboplatin to trastuzumab/paclitaxel
improves efficacy in HER2- overexpressing metastatic breast
cancer. Clin Breast Cancer 2003;3(6):378-80.
Alberti AM. A Phase II study of docetaxel (T) and
carboplatin (CBP) as second line chemotherapy in metastatic
breast cancer. Proc ASCO 2000:Abstract
438.
Brufsky AM et al. A phase II study of carboplatin
and docetaxel as first line chemotherapy for metastatic
breast cancer. Proc ASCO 2002:Abstract
2020.
Crown JP. The platinum agents: A role in breast
cancer treatment? Semin Oncol 2001;28(1 Suppl
3):28-37. Abstract.
Donaldson LA et al. A phase I/II study of carboplatin,
vinorelbine and capecitabine in patients with metastatic
breast cancer. Proc ASCO 2002:Abstract
1960.
Franco S et al. Neoadjuvant (NEO) treatment of
locally advanced and inflammatory breast cancer with weekly
taxotere and carboplatin in tumors that do not overexpress
HER-2. Proc ASCO 2002:Abstract
2048.
Hanna N et al. Phase I trial of carboplatin and
paclitaxel with escalating doses of oral topotecan in patients
with solid tumors. Am J Clin Oncol 2003;26(2):200-2.
Abstract.
Kallab AK et al. A phase II study of weekly paclitaxel
and carboplatin in metastatic breast cancer. Proc
ASCO 2002:Abstract
1953.
Kosmas C et al. Phase I study of vinorelbine and
carboplatin combination in patients with taxane and anthracycline
pretreated advanced breast cancer. Oncology 2002;62(2):103-9.
Abstract.
Loesch D et al. Phase II multicenter trial of a
weekly paclitaxel and carboplatin regimen in patients with
advanced breast cancer. J Clin Oncol 2002;20(18):3857-64.
Abstract.
Martin M. Platinum compounds in the treatment of
advanced breast cancer. Clin Breast Cancer 2001;2(3):190-208;discussion
209. Abstract.
Mavroudis D et al. Salvage treatment of metastatic
breast cancer with docetaxel and carboplatin. A multicenter
phase II trial. Oncology 2003;64(3):207-12.Abstract.
O'Rourke M et al. Efficacy and tolerability of
a weekly taxol (T) plus carboplatin (C) regimen in patients <65
years versus ? years with advanced breast cancer (ABC). Proc
ASCO 2002:Abstract 1967.Abstract.
Patton JF et al. Weekly paclitaxel, doxorubicin,
and carboplatin in the treatment of metastatic breast cancer:
A Minnie Pearl Research Network Phase II trial. Proc
ASCO 2001:Abstract
2032.
Robert N et al. Phase III comparative study of
trastuzumab and paclitaxel with and without carboplatin
in patients with HER-2/neu positive advanced breast cancer. Breast
Cancer Res Treat 2002;Abstract
35.
Robert NJ et al. Toxicity profiles: A comparative
study of Herceptin (trastuzumab) and taxol (paclitaxel)
versus herceptin, taxol, and carboplatin in HER-2 positive
patients with advanced breast cancer. Breast Cancer
Res Treat 2001;Abstract
529.
Rodenhuis S et al. Randomized Phase III study of
high-dose chemotherapy with cyclophosphamide, thiotepa
and carboplatin in operable breast cancer with 4 or more
axillary lymph nodes. Proc ASCO 2000:Abstract
286.
Slamon DJ et al. Phase II pilot study of herceptin
combined with taxotere and carboplatin (TCH) in metastatic
breast cancer (MBC) patients overexpressing the HER2-Neu
protooncogene a pilot study of the UCLA Network. Proc
ASCO 2001:Abstract
193.
Yardley DA et al. Final results of the Minnie Pearl
Cancer Research Network first-line trial of weekly paclitaxel/carboplatin/trastuzumab
in metastatic breast cancer. Breast Cancer Res
Treat 2002;Abstract
439.
|
